Market Closed -
Nasdaq Stockholm
12:00:00 2024-07-12 pm EDT
|
5-day change
|
1st Jan Change
|
0.104
SEK
|
+16.20%
|
|
+1.96%
|
+3.59%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
205.6
|
246.2
|
111.9
|
50.31
|
9.884
|
22.46
|
-
|
-
|
Enterprise Value (EV)
1 |
143.9
|
189.8
|
82.59
|
50.31
|
9.884
|
21.46
|
-18.54
|
18.46
|
P/E ratio
|
-
|
-
|
-
|
-1.16
x
|
-0.46
x
|
-0.8
x
|
-0.58
x
|
-0.58
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
5,712
x
|
-
|
6,219
x
|
-
|
-
|
-
|
-
|
-
|
EV / Revenue
|
3,997
x
|
-
|
4,588
x
|
-
|
-
|
-
|
-
|
-
|
EV / EBITDA
|
-4.33
x
|
-4.03
x
|
-1.91
x
|
-
|
-
|
-0.83
x
|
0.53
x
|
-0.5
x
|
EV / FCF
|
-3.97
x
|
-4.21
x
|
-1.87
x
|
-
|
-
|
-0.83
x
|
0.53
x
|
-0.5
x
|
FCF Yield
|
-25.2%
|
-23.7%
|
-53.5%
|
-
|
-
|
-121%
|
189%
|
-200%
|
Price to Book
|
2.87
x
|
3.67
x
|
2.75
x
|
-
|
-
|
1.04
x
|
0.39
x
|
1.16
x
|
Nbr of stocks (in thousands)
|
49,080
|
58,063
|
63,677
|
98,445
|
98,445
|
215,926
|
-
|
-
|
Reference price
2 |
4.190
|
4.240
|
1.758
|
0.5110
|
0.1004
|
0.1040
|
0.1040
|
0.1040
|
Announcement Date
|
2/14/20
|
2/12/21
|
2/22/22
|
2/17/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
0.036
|
-
|
0.018
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-33.24
|
-47.08
|
-43.23
|
-
|
-
|
-26
|
-35
|
-37
|
EBIT
1 |
-35.03
|
-48.88
|
-45.03
|
-
|
-
|
-28
|
-38
|
-39
|
Operating Margin
|
-97,305.56%
|
-
|
-250,155.56%
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-
|
-
|
-
|
-28
|
-38
|
-39
|
Net income
1 |
-
|
-
|
-
|
-42.47
|
-22.99
|
-28
|
-38
|
-39
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-
|
-
|
-
|
-0.4400
|
-0.2200
|
-0.1300
|
-0.1800
|
-0.1800
|
Free Cash Flow
1 |
-36.22
|
-45.06
|
-44.14
|
-
|
-
|
-26
|
-35
|
-37
|
FCF margin
|
-100,602.78%
|
-
|
-245,238.89%
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/14/20
|
2/12/21
|
2/22/22
|
2/17/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
61.8
|
56.3
|
29.4
|
-
|
-
|
1
|
41
|
4
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-36.2
|
-45.1
|
-44.1
|
-
|
-
|
-26
|
-35
|
-37
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
1.460
|
1.160
|
0.6400
|
-
|
-
|
0.1000
|
0.2700
|
0.0900
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.99
|
0.18
|
0.89
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
2,752.78%
|
-
|
4,955.56%
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/14/20
|
2/12/21
|
2/22/22
|
2/17/23
|
2/27/24
|
-
|
-
|
-
|
|
1st Jan change
|
Capi.
|
---|
| +3.59% | 2.13M | | +7.04% | 73.13B | | +31.10% | 10.38B | | +37.94% | 5.16B | | -17.33% | 4.73B | | +21.49% | 3.81B | | +24.92% | 2.26B | | -36.84% | 1.88B | | -43.31% | 1.77B | | -0.50% | 1.64B |
Specialty & Advanced Pharmaceuticals
|